Association of CYP2C19*2/3 gene polymorphism with lung cancer in Moroccan population

被引:0
|
作者
Berradi, Hind [1 ]
Kaanane, Houda [1 ]
Hassani Idrissi, Hind [1 ]
Elkadmiri, Nadia [3 ]
Benchakroun, Nadia [2 ]
Benider, Abdellatif [2 ]
Izaabel, El Hassan [4 ]
Nadifi, Sellama [1 ]
机构
[1] Hassan II Univ Casablanca, Fac Med & Pharm, Lab Cellular & Mol Pathol, BP 9154, Casablanca, Morocco
[2] CHU Ibn Rochd, Mohamed VI Ctr Canc Treatment, Anat Pathol Serv, Casablanca, Morocco
[3] IBN ZOHR Univ, Fac Polydisciplinaire Taroudant, BP 271, Taroudant 83000, Morocco
[4] Univ Ibn Zohr, Fac Sci, Cellular Biol & Mol Genet Lab, Agadir, Morocco
来源
GENE REPORTS | 2021年 / 25卷
关键词
CYP2C19*2; Cyp2c19*3; Lung cancer; Smoking; Predisposition; POOR METABOLIZERS; INCREASED RISK; CYP2C19; 2C19;
D O I
10.1016/j.genrep.2021.101314
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: As it is the case for all kinds of cancer; lung cancer is a multifactorial disease. The interaction between both Exposures to different carcinogens and individual genetic backgrounds modulate the disease risk. Cytochrome P450 family is one of the main enzymes involved in the metabolism of these carcinogens. Therefore, polymorphisms of genes encoding for the cyp450 enzymes can be responsible for the inter-individual differences in lung cancer susceptibility. In this study, we chose to focus on the Cyp2c19, as one of the crucial cyp450 enzymes associated with metabolism of a number of drugs and xenobiotics and its association with the lung cancer risk. Methods: Peripheral blood from a total of 115 Moroccan patients diagnosed with lung cancer and 105 healthy subjects was collected. The genotyping of CYP2C19*2 and CYP2C19*3 polymorphisms was carried out using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technic. Results: We found that the frequency of both CYP2C19*2 (GA+AA) genotype and CYP2C19*A allele were significantly more frequent in lung cancer patients than that in control subjects (24.3% vs 13.3%; p = 0.04 and 14.35% vs 7.15%; p = 0.01 respectively). We also found that the CYP2C19*3 A allele was only found in lung cancer patient with a frequency of 10% (p = 0.007). Consequently, the frequency of the CYP2C19*3 (GA + AA) genotype was also significantly more prevalent in lung cancer patients than that in controls (20% vs 0.00%; p = 0.005). We also found that smoking is associated to a higher lung cancer risk in participants carrying CYP2C19*3 or CYP2C19*2 GG genotypes (p < 0.0001, OR = 26.42, 95%CI = 12.38-56.36) and (p < 0.0001, OR = 24,44, 95%CI = 11,13-53,65). While the binary logistic regression analysis demonstrates that interaction of CYP2C19*2 with smoking has no effect on the lung cancer risk, unlike the CYP2C19*3 which coexisted with smoking increases lung cancer risk even more. Conclusion: These findings indicate that the CYP2C19*2 and CYP2C19*3 polymorphisms are significantly associated with lung cancer in Moroccan population. In addition, that the coexistence of CYP2C19*3 with smoking increased lung cancer risk even more.
引用
收藏
页数:5
相关论文
共 50 条
  • [11] Genetic polymorphism of CYP2C19 in Maharashtrian population
    Ghodke, Yogita
    Joshi, Kalpana
    Arya, Yashendra
    Radkar, Anjali
    Chiplunkar, Aditi
    Shintre, Pooja
    Patwardhan, Bhushan
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2007, 22 (12) : 907 - 915
  • [12] Genetic Polymorphism of CYP2C19 in Pakistani Population
    Riaz, Sana
    Din, Sadia Muhammad
    Tareen, Muhammad Usman
    Tariq, Fizza
    Latif, Yusra
    Siddiqi, Saima
    Sultan, Aneesa
    Mansoor, Atika
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2019, 18 (02): : 1097 - 1102
  • [13] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Zalloum, Imad
    Hakooz, Nancy
    Arafat, Tawfiq
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (04) : 4195 - 4200
  • [14] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Imad Zalloum
    Nancy Hakooz
    Tawfiq Arafat
    Molecular Biology Reports, 2012, 39 : 4195 - 4200
  • [15] Analysis of the CYP2C19*2 and*3 gene variants in a Romanian population
    Buzoianu, A. D.
    Trifa, A. P.
    Popp, R. A.
    Militaru, C.
    Bocsan, C.
    Pop, I., V
    9TH CONGRESS OF THE EUROPEAN ASSOCIATION FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS - EACPT, 2009, : 47 - +
  • [16] Association Between CYP2C19 Polymorphism and Depressive Symptoms
    Sim, Sarah C.
    Nordin, Linn
    Andersson, Therese M. -L.
    Virding, Susanne
    Olsson, Marita
    Pedersen, Nancy L.
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2010, 153B (06) : 1160 - 1166
  • [17] CYP2C19*3 polymorphism in patients with endometriosis
    Bento, I. A.
    Silva, K. S. F. e
    Moura, K. K. V. O.
    Ribeiro Junior, C. L.
    da Costa, I. R.
    GENETICS AND MOLECULAR RESEARCH, 2019, 18 (02)
  • [18] The CYP2C19 enzyme polymorphism
    Wedlund, PJ
    PHARMACOLOGY, 2000, 61 (03) : 174 - 183
  • [19] Example of the Contribution of Pharmacogenetics to Pharmacovigilance in Morocco: Prevalence of the CYP2C19*2 Polymorphism and Clopidogrel Resistance in Moroccan Population
    Lamzouri, A.
    El Rherbi, A.
    Sefiani, H.
    Benabdallah, G.
    Tebaa, A.
    Soulaymani Bencheikh, R.
    Sefiani, A.
    DRUG SAFETY, 2019, 42 (10) : 1267 - 1267
  • [20] Example of Using Pharmacogenetics for Drug Safety: Prevalence of the Cyp2c19*2 Polymorphism and Clopidogrel Resistance in Moroccan Population
    Lamzouri, A.
    Laarabi, F. Z.
    Lyahyai, J.
    Adadi, N.
    El Rherbi, A.
    Tebaa, A.
    Bencheikh, R. Soulaymani
    Sefiani, A.
    DRUG SAFETY, 2018, 41 (11) : 1173 - 1174